| Autor: |
Wasfy JH; Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: jwasfy@mgh.harvard.edu., Januzzi JL Jr; Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Baim Institute for Clinical Research, Boston, Massachusetts, USA. |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of the American College of Cardiology [J Am Coll Cardiol] 2024 Oct 29; Vol. 84 (18), pp. 1730-1732. |
| DOI: |
10.1016/j.jacc.2024.08.050 |
| Abstrakt: |
Competing Interests: Funding Support and Author Disclosures Dr Januzzi is a Trustee of the American College of Cardiology; is a Director at Imbria Pharmaceuticals; is an Advisor at Jana Care; has received grant support from Abbott, Applied Therapeutics, HeartFlow Inc, Innolife, and Roche Diagnostics; has received consulting income from Abbott, Janssen, Novartis, Merck, and Roche Diagnostics; and participates in clinical endpoint committees/data safety monitoring boards for Abbott, AbbVie, Bayer, CVRx, Intercept, Pfizer, and Takeda. Dr Wasfy has reported that he has no relationships relevant to the contents of this paper to disclose. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
